| abstract |
The present invention relates to cognate structures (e.g., antigens, counterreceptors, etc.), wild type IgG, IgA or Ig3 hinge action regions (i.e., IgE CH2 region polypeptides or mutant IgG1 hinge region polypeptides having zero, one or two cysteine residues). And a novel binding domain that is capable of predominantly generating ADCC and / or CDC as a polypeptide, characterized by a binding domain for immunoglobulin CH2 and CH3 domains and impairing their ability to form disulfide-linked multimers. It relates to an immunoglobulin fusion protein. Fusion proteins may be recombinantly produced at high expression levels. The invention also provides related compositions and methods, including cell surface morphology of the fusion protein, immunotherapeutic use of the fusion protein, and immunotherapy of a polynucleotide encoding the fusion protein, for example. |